Pathogenesis of Acute Leukemia, Lymphoproliferative Disorders, and Myeloproliferative Disorders
N/A
1 Year
N/A
1 Year
N/A
Open (Enrolling by invite only)
Both
Acute Leukemia, Lymphoproliferative Disorders, Myeloproliferative Disorders
Both
Acute Leukemia, Lymphoproliferative Disorders, Myeloproliferative Disorders
Trial Information
Pathogenesis of Acute Leukemia, Lymphoproliferative Disorders, and Myeloproliferative Disorders
Inclusion Criteria:
- Suspected or confirmed diagnosis of AL, LPD, MDS, or MPD
- Male or female of all ages
- Willing and able to sign informed consent
- Willing guardian consent for participants under 18 years of age
Exclusion Criteria:
- No suspected or confirmed diagnosis of acute leukemias (AL), lymphoproliferative
disorders (LPD), myelodysplastic syndromes (MDS), or myeloproliferative diseases
(MPD)
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
The frequency of activating mutations of tyrosine kinases, and phosphatases in patients with acute leukemias (AL), lymphoproliferative disorders(LPD), myelodysplastic syndromes(MDS), and myeloproliferative disease(MPD)
Outcome Time Frame:
Duration of the study; Up to 5 years
Safety Issue:
No
Authority:
United States: Institutional Review Board
Study ID:
IRB00004422
NCT ID:
NCT01728402
Start Date:
September 2008
Completion Date:
October 2013
Related Keywords:
- Acute Leukemia
- Lymphoproliferative Disorders
- Myeloproliferative Disorders
- Leukemia
- Lymphoproliferative Disorders
- Myeloproliferative Disorders
- Acute Disease
- Hematologic Neoplasms
Name | Location |
|---|---|
| OHSU Knight Cancer Institute | Portland, Oregon 97239 |
